论文部分内容阅读
[目的]探讨柳氮磺胺吡啶与益生菌联合治疗溃疡性结肠炎临床疗效。[方法]按照随机数字表法将2013年1月~2015年6月60例溃疡性结肠炎患者分组为对照组(柳氮磺胺吡啶)与治疗组(柳氮磺胺吡啶与益生菌联合),各30例。比较2组患者治疗前、后白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、疾病活动指数(DAI)及肿瘤坏死因子-α(TNF-α)变化;统计2组患者临床疗效及不良反应。[结果]治疗前,2组患者DAI评分、IL-6、IL-8及TNF-α水平比较,P>0.05;治疗后,2组患者DAI评分、IL-6、IL-8及TNF-α较治疗前明显下降,然治疗组下降较对照组显著,P<0.05。治疗组治疗总有效率93.3%明显高于对照组66.7%,P<0.05治疗期间,2组各1例轻度头痛现象,然均未采取任何措施治疗,症状于30min后自行消失,无任何严重性不良反应发生。[结论]应用柳氮磺胺吡啶与益生菌联合治疗溃疡性结肠炎可显著改善患者临床症状,提高临床疗效,且无明显不良反应发生,因此可值得推广应用。
[Objective] To investigate the clinical efficacy of sulfasalazine combined with probiotics in the treatment of ulcerative colitis. [Methods] Sixty patients with ulcerative colitis were divided into control group (sulfasalazine) and treatment group (sulfasalazine combined with probiotics) according to the random number table method from January 2013 to June 2015. 30 cases. The changes of IL-6, IL-8, disease activity index (DAI) and tumor necrosis factor-α (TNF-α) in two groups before and after treatment were compared. Two groups of patients with clinical efficacy and adverse reactions. [Results] Before treatment, DAI score, IL-6, IL-8 and TNF-α levels in two groups were significantly higher than those before treatment Compared with before treatment decreased significantly, while the treatment group decreased significantly than the control group, P <0.05. The total effective rate of the treatment group was 93.3%, which was significantly higher than that of the control group (66.7%). During the treatment of P <0.05, one case of mild headache occurred in each of the two groups. However, no measures were taken to treat them. The symptoms disappeared on their own after 30 minutes without any serious Sexual adverse reactions occur. [Conclusion] The combination of sulfasalazine and probiotics in the treatment of ulcerative colitis can significantly improve the clinical symptoms and improve the clinical efficacy, and no obvious adverse reactions, it may be worth popularizing and applying.